Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation | Zendy

Samuel A. Stoner | Zendy; Ming Yan | Zendy; Katherine Liu | Zendy; Kei-Ichiro Arimoto | Zendy; Takahiro Shima | Zendy; HuanYou Wang | Zendy; D. T. Johnson | Zendy; Rafael Bejar | Zendy; Catriona Jamieson | Zendy; KunLiang Guan | Zendy; DongEr Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation

Author(s) -

Samuel A. Stoner,

Ming Yan,

Katherine Liu,

Kei-Ichiro Arimoto,

Takahiro Shima,

HuanYou Wang,

D. T. Johnson,

Rafael Bejar,

Catriona Jamieson,

KunLiang Guan,

DongEr Zhang

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019000170

Subject(s) - biology , cancer research , myeloproliferative neoplasm , innate immune system , myeloid , immunology , myelofibrosis , immune system , bone marrow

Deletions of chromosome 20q are frequent abnormalities in myelodysplastic syndrome (MDS) and myeloproliferative neoplasms. Stoner et al identify STK4, which encodes Hippo kinase MST1, as the candidate gene from the deleted region that, when deleted, promotes features of MDS and induces myelofibrosis in the presence of JAK2V617F through modulation of inflammatory pathways.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research